The content on this site is intended for healthcare professionals only
Reductions in breast density predict potential benefit of tamoxifen
Use of written forms doubles breast cancer detection rate
Breast cancer patients may have better option to reduce oestrogen levels
Hormone supplements reduce death from breast cancer
Zoledronic acid may have anti-tumour properties
Herceptin Increases event-free survival in locally advanced HER2-postive breast cancer
New genetic modelling improves screening for breast cancer
New biomarker predicts anthracycline response
Continuing adjuvant tamoxifen leads to higher quality of life
BIG 1-98: Letrozole vs tamoxifen
Poor prognosis on small, HER2 positive tumours
Predictive value of HER2 and topoisomerase II alpha in early breast cancer patients treated with CMF or anthracycline-based adjuvant therapy
10 new genes increase risk of breast cancer
Various molecular imaging devices for non-invasive assessment of protein function and gene-expression pathways
Prophylactic surgery for BRCA1 and BRCA2 carriers
Circulating tumour cells
Molecular mechanisms of breast cancer tumours
Sentinel node biopsy and other breast cancer surgery techniques
Breast cancer stem cell regulation
Clinical research needs better interpretation
Extrapolating info from clinical trials to individual patients
Tamoxifen vs Aromatase Inhibitors and highlights of San Antonio Breast Cancer Symposium
Professor José Baselga, ESMO and Professor Martine Piccart, BIG
Endoxifen levels in Breast Cancer patients and testing for CYP2D6
Breast Cancer Cell Apoptosis
New data from the BIG 1-98 breast cancer trial
